The Efficacy, Safety And Toleration Of CP-866,087 In Pre-Menopausal Women With Female Sexual Arousal Disorder.

A Phase 2a Multi-Centre, Double Blind, Placebo Controlled Cross-Over Trial To Investigate The Efficacy, Safety And Toleration Of CP-866,087 In Pre-Menopausal Women Diagnosed With Female Sexual Arousal Disorder (FSAD).

CP-866,087 is a non-hormonal compound, acting on the central nervous system, which has been shown in animal models to restore sexual function.

Inclusion Criteria:

• healthy pre-menopausal women
• primary female sexual arousal disorder causing distress
• on stable use of oral contraceptives

Exclusion Criteria:

• any other significant disease causing Female Sexual Dysfunction including psychiatric disease
• subjects on drugs known to cause Female Sexual Dysfunction
• subjects who have given birth in the last 12 months or who are planning to become pregnant during the study